Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Previous Immune Checkpoint Inhibitor Treatment to Increase the Efficacy of Docetaxel and Ramucirumab Combination Chemotherapy.

Harada D, Takata K, Mori S, Kozuki T, Takechi Y, Moriki S, Asakura Y, Ohno T, Nogami N.

Anticancer Res. 2019 Sep;39(9):4987-4993. doi: 10.21873/anticanres.13688.

PMID:
31519605
2.

Therapeutic Outcomes of 15 Postoperative Bronchopleural Fistulas Including Seven Endoscopic Interventions.

Ueno T, Maki Y, Sugimoto R, Suehisa H, Yamashita M, Harada D, Kozuki T, Nogami N.

Acta Med Okayama. 2019 Aug;73(4):325-331. doi: 10.18926/AMO/56934.

3.

A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY).

Ninomiya K, Hata T, Yoshioka H, Ohashi K, Bessho A, Hosokawa S, Ishikawa N, Yamasaki M, Shibayama T, Aoe K, Kozuki T, Harita S, Ueda Y, Murakami T, Fujimoto N, Yanai H, Toyooka S, Takata M, Hotta K, Kiura K; HER2-CS Network.

Chest. 2019 Aug;156(2):357-366. doi: 10.1016/j.chest.2019.01.011. Epub 2019 May 6.

PMID:
31072612
4.

The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV.

Akamatsu H, Ninomiya K, Kenmotsu H, Morise M, Daga H, Goto Y, Kozuki T, Miura S, Sasaki T, Tamiya A, Teraoka S, Tsubata Y, Yoshioka H, Hattori Y, Imamura CK, Katsuya Y, Matsui R, Minegishi Y, Mizugaki H, Nosaki K, Okuma Y, Sakamoto S, Sone T, Tanaka K, Umemura S, Yamanaka T, Amano S, Hasegawa K, Morita S, Nakajima K, Maemondo M, Seto T, Yamamoto N.

Int J Clin Oncol. 2019 Jul;24(7):731-770. doi: 10.1007/s10147-019-01431-z. Epub 2019 May 2.

5.

Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study.

Katsuya Y, Horinouchi H, Seto T, Umemura S, Hosomi Y, Satouchi M, Nishio M, Kozuki T, Hida T, Sukigara T, Nakamura K, Kuchiba A, Ohe Y.

Eur J Cancer. 2019 May;113:78-86. doi: 10.1016/j.ejca.2019.03.012. Epub 2019 Apr 13.

6.

A phase I/II trial of weekly nab-paclitaxel for pretreated non-small-cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement.

Harada D, Kozuki T, Nogami N, Bessho A, Hosokawa S, Fukamatsu N, Hotta K, Ohashi K, Kubo T, Yoshioka H, Yokoyama T, Sone N, Kuyama S, Kudo K, Yasugi M, Takigawa N, Oze I, Kiura K.

Asia Pac J Clin Oncol. 2019 Aug;15(4):250-256. doi: 10.1111/ajco.13147. Epub 2019 Apr 1.

PMID:
30938103
7.

Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors.

Fujiwara Y, Iguchi H, Yamamoto N, Hayama M, Nii M, Ueda S, Komuro K, Sugimoto M, Vlahovic G, Kozuki T.

Cancer Sci. 2019 May;110(5):1715-1723. doi: 10.1111/cas.14003. Epub 2019 Apr 13.

8.

The effect of comprehensive physiotherapy-based rehabilitation on stooped posture in Parkinson's disease.

Kawami Y, Marumoto K, Shiomi Y, Okinishi M, Kozuki T, Oyabu H, Yokoyama K, Nikaido Y, Akisue T.

J Phys Ther Sci. 2018 Dec;30(12):1440-1445. doi: 10.1589/jpts.30.1440. Epub 2018 Nov 21.

9.

Phase 2 Study of Afatinib Alone or Combined With Bevacizumab in Chemonaive Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: AfaBev-CS Study Protocol.

Ninomiya T, Ishikawa N, Inoue K, Kubo T, Yasugi M, Shibayama T, Maeda T, Fujitaka K, Kodani M, Yokoyama T, Kuyama S, Ochi N, Ueda Y, Miyoshi S, Kozuki T, Amano Y, Kubota T, Sugimoto K, Bessho A, Ishii T, Watanabe K, Oze I, Hotta K, Kiura K.

Clin Lung Cancer. 2019 Mar;20(2):134-138. doi: 10.1016/j.cllc.2018.10.008. Epub 2018 Nov 1.

PMID:
30514667
10.

First-line onartuzumab plus erlotinib treatment for patients with MET-positive and EGFR mutation-positive non-small-cell lung cancer.

Kishi K, Sakai H, Seto T, Kozuki T, Nishio M, Imamura F, Nokihara H, Satouchi M, Nakagawa S, Tahata T, Nakagawa K.

Cancer Treat Res Commun. 2019;18:100113. doi: 10.1016/j.ctarc.2018.10.004. Epub 2018 Oct 31.

11.

Study Protocol: Phase-Ib Trial of Nivolumab Combined With Metformin for Refractory/Recurrent Solid Tumors.

Kubo T, Ninomiya T, Hotta K, Kozuki T, Toyooka S, Okada H, Fujiwara T, Udono H, Kiura K.

Clin Lung Cancer. 2018 Nov;19(6):e861-e864. doi: 10.1016/j.cllc.2018.07.010. Epub 2018 Aug 9.

PMID:
30172698
12.

Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer.

Hata A, Harada D, Okuda C, Kaji R, Masuda Y, Takechi Y, Kozuki T, Nogami N, Katakami N.

Oncotarget. 2018 Jun 12;9(45):27789-27796. doi: 10.18632/oncotarget.25578. eCollection 2018 Jun 12.

13.

A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol.

Fujimoto N, Aoe K, Kozuki T, Oze I, Kato K, Kishimoto T, Hotta K.

Clin Lung Cancer. 2018 Sep;19(5):e705-e707. doi: 10.1016/j.cllc.2018.05.001. Epub 2018 May 9.

14.

A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer.

Hotta K, Aoe K, Kozuki T, Ohashi K, Ninomiya K, Ichihara E, Kubo T, Ninomiya T, Chikamori K, Harada D, Nogami N, Hirata T, Hinotsu S, Toyooka S, Kiura K.

J Thorac Oncol. 2018 Feb;13(2):273-279. doi: 10.1016/j.jtho.2017.10.032. Epub 2017 Dec 5.

15.

A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404.

Ninomiya T, Nogami N, Kozuki T, Harada D, Kubo T, Ohashi K, Kuyama S, Kudo K, Bessho A, Fukamatsu N, Fujimoto N, Aoe K, Shibayama T, Sugimoto K, Takigawa N, Hotta K, Kiura K.

Lung Cancer. 2018 Jan;115:103-108. doi: 10.1016/j.lungcan.2017.11.025. Epub 2017 Nov 28.

PMID:
29290249
16.

Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.

Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Asabe R, Tanaka T, Tamura T.

Lancet. 2017 Jul 1;390(10089):29-39. doi: 10.1016/S0140-6736(17)30565-2. Epub 2017 May 10.

PMID:
28501140
17.

Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint.

Kozuki T, Chikamori K, Surleac MD, Micluta MA, Petrescu AJ, Norris EJ, Elson P, Hoeltge GA, Grabowski DR, Porter ACG, Ganapathi RN, Ganapathi MK.

Nucleic Acids Res. 2017 Jun 2;45(10):5995-6010. doi: 10.1093/nar/gkx325.

18.

Erratum to: Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer.

Yamamoto N, Goto K, Nishio M, Chikamori K, Hida T, Maemondo M, Katakami N, Kozuki T, Yoshioka H, Seto T, Tajima K, Tamura T.

Int J Clin Oncol. 2017 Feb;22(1):79. doi: 10.1007/s10147-016-1052-3. No abstract available.

PMID:
27747455
19.

Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer.

Yamamoto N, Goto K, Nishio M, Chikamori K, Hida T, Maemondo M, Katakami N, Kozuki T, Yoshioka H, Seto T, Tajima K, Tamura T.

Int J Clin Oncol. 2017 Feb;22(1):70-78. doi: 10.1007/s10147-016-1039-0. Epub 2016 Sep 22. Erratum in: Int J Clin Oncol. 2017 Feb;22(1):79.

20.

A phase II study of topotecan and cisplatin with sequential thoracic radiotherapy in elderly patients with small-cell lung cancer: Okayama Lung Cancer Study Group 0102.

Kubo T, Fujiwara K, Hotta K, Okada T, Kuyama S, Harita S, Ninomiya T, Kamei H, Hosokawa S, Bessho A, Maeda T, Kozuki T, Fujimoto N, Ninomiya K, Takemoto M, Kanazawa S, Takigawa N, Tabata M, Tanimoto M, Ueoka H, Kiura K.

Cancer Chemother Pharmacol. 2016 Oct;78(4):769-74. doi: 10.1007/s00280-016-3135-2. Epub 2016 Aug 20.

PMID:
27544764
21.

Trastuzumab Emtansine in HER2+ Recurrent Metastatic Non-Small-Cell Lung Cancer: Study Protocol.

Ohashi K, Hotta K, Hirata T, Aoe K, Kozuki T, Ninomiya K, Kayatani H, Yanai H, Toyooka S, Hinotsu S, Takata M, Kiura K.

Clin Lung Cancer. 2017 Jan;18(1):92-95. doi: 10.1016/j.cllc.2016.06.014. Epub 2016 Jul 9.

PMID:
27497829
22.

Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.

Goto K, Ohe Y, Shibata T, Seto T, Takahashi T, Nakagawa K, Tanaka H, Takeda K, Nishio M, Mori K, Satouchi M, Hida T, Yoshimura N, Kozuki T, Imamura F, Kiura K, Okamoto H, Sawa T, Tamura T; JCOG0605 investigators.

Lancet Oncol. 2016 Aug;17(8):1147-1157. doi: 10.1016/S1470-2045(16)30104-8. Epub 2016 Jun 14.

PMID:
27312053
23.

Feasibility study of first-line chemotherapy using Pemetrexed and Bevacizumab for advanced or recurrent nonsquamous non-small cell lung cancer in elderly patients: TORG1015.

Kozuki T, Nogami N, Kitajima H, Iwasawa S, Sakaida E, Takiguchi Y, Ikeda S, Yoshida M, Kato T, Miyamoto S, Sakamaki K, Shinkai T, Watanabe K.

BMC Cancer. 2016 May 12;16:306. doi: 10.1186/s12885-016-2338-6.

24.

Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience.

Kudo K, Hotta K, Bessho A, Nogami N, Kozuki T, Kuyama S, Inoue K, Harita S, Okada T, Gemba K, Fujii M, Takigawa N, Oda N, Tanimoto M, Kiura K.

Cancer Chemother Pharmacol. 2016 May;77(5):1005-9. doi: 10.1007/s00280-015-2910-9. Epub 2016 Mar 31.

PMID:
27029623
25.

Skin problems and EGFR-tyrosine kinase inhibitor.

Kozuki T.

Jpn J Clin Oncol. 2016 Apr;46(4):291-8. doi: 10.1093/jjco/hyv207. Epub 2016 Jan 29. Review.

26.

Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.

Ichihara E, Hotta K, Nogami N, Kuyama S, Kishino D, Fujii M, Kozuki T, Tabata M, Harada D, Chikamori K, Aoe K, Ueoka H, Hosokawa S, Bessho A, Hisamoto-Sato A, Kubo T, Oze I, Takigawa N, Tanimoto M, Kiura K.

J Thorac Oncol. 2015 Mar;10(3):486-91. doi: 10.1097/JTO.0000000000000434.

27.

A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0501.

Nogami N, Takigawa N, Hotta K, Segawa Y, Kato Y, Kozuki T, Oze I, Kishino D, Aoe K, Ueoka H, Kuyama S, Harita S, Okada T, Hosokawa S, Inoue K, Gemba K, Shibayama T, Tabata M, Takemoto M, Kanazawa S, Tanimoto M, Kiura K.

Lung Cancer. 2015 Feb;87(2):141-7. doi: 10.1016/j.lungcan.2014.11.001. Epub 2014 Nov 8.

PMID:
25534129
28.

Capnocytophaga canimorsus bacteremia presenting with acute cholecystitis after a dog bite.

Nishioka H, Kozuki T, Kamei H.

J Infect Chemother. 2015 Mar;21(3):215-7. doi: 10.1016/j.jiac.2014.09.001. Epub 2014 Oct 23.

PMID:
25445385
29.

Phase II study of Amrubicin combined with carboplatin for thymic carcinoma and invasive thymoma: North Japan Lung Cancer group study 0803.

Inoue A, Sugawara S, Harada M, Kobayashi K, Kozuki T, Kuyama S, Maemondo M, Asahina H, Hisamoto A, Nakagawa T, Hotta K, Nukiwa T.

J Thorac Oncol. 2014 Dec;9(12):1805-9. doi: 10.1097/JTO.0000000000000362.

30.

Phase I dose-escalation study evaluating safety, tolerability and pharmacokinetics of MEDI-573, a dual IGF-I/II neutralizing antibody, in Japanese patients with advanced solid tumours.

Iguchi H, Nishina T, Nogami N, Kozuki T, Yamagiwa Y, Yagawa K.

Invest New Drugs. 2015 Feb;33(1):194-200. doi: 10.1007/s10637-014-0170-x. Epub 2014 Oct 25.

PMID:
25342141
31.

A phase II study of S-1 chemotherapy with concurrent thoracic radiotherapy in elderly patients with locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0801.

Aoe K, Takigawa N, Hotta K, Maeda T, Kishino D, Nogami N, Tabata M, Harita S, Okada T, Kubo T, Hosokawa S, Fujiwara K, Gemba K, Yasugi M, Kozuki T, Kato Y, Katsui K, Kanazawa S, Ueoka H, Tanimoto M, Kiura K.

Eur J Cancer. 2014 Nov;50(16):2783-90. doi: 10.1016/j.ejca.2014.07.024. Epub 2014 Aug 26.

PMID:
25172295
32.

[Pulmonary non-tuberculous mycobacteriosis complicated with lung cancer].

Suehisa H, Matsuda F, Kawamoto H, Ueno T, Sawada S, Yamashita M, Yamamoto S, Harada D, Kitajima H, Kozuki T, Nogami N, Takahata H.

Kyobu Geka. 2014 Jul;67(7):549-52. Japanese.

PMID:
25137324
33.

Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA).

Kawaguchi T, Ando M, Asami K, Okano Y, Fukuda M, Nakagawa H, Ibata H, Kozuki T, Endo T, Tamura A, Kamimura M, Sakamoto K, Yoshimi M, Soejima Y, Tomizawa Y, Isa S, Takada M, Saka H, Kubo A.

J Clin Oncol. 2014 Jun 20;32(18):1902-8. doi: 10.1200/JCO.2013.52.4694. Epub 2014 May 19.

PMID:
24841974
34.

Factor associated with failure to administer subsequent treatment after progression in the first-line chemotherapy in EGFR-mutant non-small cell lung cancer: Okayama Lung Cancer Study Group experience.

Kato Y, Hotta K, Takigawa N, Nogami N, Kozuki T, Sato A, Ichihara E, Kudo K, Oze I, Tabata M, Shinkai T, Tanimoto M, Kiura K.

Cancer Chemother Pharmacol. 2014 May;73(5):943-50. doi: 10.1007/s00280-014-2425-9. Epub 2014 Mar 16.

PMID:
24633759
35.

A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC).

Goto K, Nishio M, Yamamoto N, Chikamori K, Hida T, Maemondo M, Katakami N, Kozuki T, Yoshioka H, Seto T, Fukuyama T, Tamura T.

Lung Cancer. 2013 Oct;82(1):109-14. doi: 10.1016/j.lungcan.2013.07.003. Epub 2013 Jul 31.

36.

Lung-cancer related chest events detected by periodical follow-up CT after stereotactic body radiotherapy for stage I primary lung cancer: retrospective analysis of incidence of lung-cancer related chest events and outcomes of salvage treatment.

Hamamoto Y, Kataoka M, Yamashita M, Nogami N, Sugawara Y, Kozuki T, Sawada S, Suehisa H, Shinohara S, Nakajima N, Shinkai T.

Jpn J Radiol. 2012 Oct;30(8):671-5. doi: 10.1007/s11604-012-0107-2. Epub 2012 Jul 20.

PMID:
22836906
37.

Nationwide surveillance of bacterial respiratory pathogens conducted by the Surveillance Committee of Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Clinical Microbiology in 2009: general view of the pathogens' antibacterial susceptibility.

Watanabe A, Yanagihara K, Matsumoto T, Kohno S, Aoki N, Oguri T, Sato J, Muratani T, Yagisawa M, Ogasawara K, Koashi N, Kozuki T, Komoto A, Takahashi Y, Tsuji T, Terada M, Nakanishi K, Hattori R, Hirako Y, Maruo A, Minamitani S, Morita K, Wakamura T, Sunakawa K, Hanaki H, Ohsaki Y, Honda Y, Sasaoka S, Takeda H, Ikeda H, Sugai A, Miki M, Nakanowatari S, Takahashi H, Utagawa M, Kobayashi N, Takasaki J, Konosaki H, Aoki Y, Shoji M, Goto H, Saraya T, Kurai D, Okazaki M, Kobayashi Y, Katono Y, Kawana A, Saionji K, Miyazawa N, Sato Y, Watanuki Y, Kudo M, Ehara S, Tsukada H, Imai Y, Watabe N, Aso S, Honma Y, Mikamo H, Yamagishi Y, Takesue Y, Wada Y, Nakamura T, Mitsuno N, Mikasa K, Kasahara K, Uno K, Sano R, Miyashita N, Kurokawa Y, Takaya M, Kuwabara M, Watanabe Y, Doi M, Shimizu S, Negayama K, Kadota J, Hiramatsu K, Morinaga Y, Honda J, Fujita M, Iwata S, Iwamoto A, Ezaki T, Onodera S, Kusachi S, Tateda K, Tanaka M, Totsuka K, Niki Y, Matsumoto T.

J Infect Chemother. 2012 Oct;18(5):609-20. doi: 10.1007/s10156-012-0434-3. Epub 2012 Jul 6.

38.

Factors affecting the local control of stereotactic body radiotherapy for lung tumors including primary lung cancer and metastatic lung tumors.

Hamamoto Y, Kataoka M, Yamashita M, Nogami N, Sugawara Y, Kozuki T, Sawada S, Suehisa H, Shinohara S, Nakajima N, Shinkai T.

Jpn J Radiol. 2012 Jun;30(5):430-4. doi: 10.1007/s11604-012-0071-x. Epub 2012 Mar 27.

PMID:
22450903
39.

Factors affecting survival time after recurrence of non-small-cell lung cancer treated with concurrent chemoradiotherapy.

Hamamoto Y, Kataoka M, Nogami N, Kozuki T, Kato Y, Shinohara S, Shinkai T.

Jpn J Radiol. 2012 Apr;30(3):249-54. doi: 10.1007/s11604-011-0040-9. Epub 2012 Feb 7.

PMID:
22311092
40.

Long-term follow-up of phase II trial of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer.

Tokuda Y, Takigawa N, Kozuki T, Kamei H, Bessho A, Tada A, Hotta K, Katsui K, Kanazawa S, Tanimoto M, Kiura K.

Acta Oncol. 2012 Apr;51(4):537-40. doi: 10.3109/0284186X.2011.631580. Epub 2011 Nov 16.

PMID:
22085375
41.

Two functional sites of phosphatidylglycerol for regulation of reaction of plastoquinone Q(B) in photosystem II.

Itoh S, Kozuki T, Nishida K, Fukushima Y, Yamakawa H, Domonkos I, Laczkó-Dobos H, Kis M, Ughy B, Gombos Z.

Biochim Biophys Acta. 2012 Feb;1817(2):287-97. doi: 10.1016/j.bbabio.2011.10.002. Epub 2011 Oct 18.

42.

Optimal dosage regimen of meropenem for pediatric patients based on pharmacokinetic/pharmacodynamic considerations.

Ohata Y, Tomita Y, Nakayama M, Kozuki T, Sunakawa K, Tanigawara Y.

Drug Metab Pharmacokinet. 2011;26(5):523-31. Epub 2011 Jul 12.

43.

STAT3 expression in activating EGFR-driven adenocarcinoma of the lung.

Takata S, Takigawa N, Segawa Y, Kubo T, Ohashi K, Kozuki T, Teramoto N, Yamashita M, Toyooka S, Tanimoto M, Kiura K.

Lung Cancer. 2012 Jan;75(1):24-9. doi: 10.1016/j.lungcan.2011.05.015.

PMID:
21684622
44.

Nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy in 2008: general view of the pathogens' antibacterial susceptibility.

Niki Y, Hanaki H, Matsumoto T, Yagisawa M, Kohno S, Aoki N, Watanabe A, Sato J, Hattori R, Koashi N, Terada M, Kozuki T, Maruo A, Morita K, Ogasawara K, Takahashi Y, Matsuda K, Nakanishi K, Sunakawa K, Takeuchi K, Fujimura S, Takeda H, Ikeda H, Sato N, Niitsuma K, Saito M, Koshiba S, Kaneko M, Miki M, Nakanowatari S, Takahashi H, Utagawa M, Nishiya H, Kawakami S, Aoki Y, Chonabayashi N, Sugiura H, Ichioka M, Goto H, Kurai D, Saraya T, Okazaki M, Yoshida K, Yoshida T, Tsukada H, Imai Y, Honma Y, Yamamoto T, Kawai A, Mikamo H, Takesue Y, Wada Y, Miyara T, Toda H, Mitsuno N, Fujikawa Y, Nakajima H, Kubo S, Ohta Y, Mikasa K, Kasahara K, Koizumi A, Sano R, Yagi S, Takaya M, Kurokawa Y, Kusano N, Mihara E, Nose M, Kuwabara M, Fujiue Y, Ishimaru T, Matsubara N, Kawasaki Y, Tokuyasu H, Masui K, Kido M, Ota T, Honda J, Kadota J, Hiramatsu K, Aoki Y, Nagasawa Z, Yanagihara K, Fujita J, Tateyama M, Totsuka K.

J Infect Chemother. 2011 Aug;17(4):510-23. doi: 10.1007/s10156-011-0214-5. Epub 2011 Mar 17.

45.

Tyrosine 656 in topoisomerase IIβ is important for the catalytic activity of the enzyme: Identification based on artifactual +80-Da modification at this site.

Grozav AG, Willard BB, Kozuki T, Chikamori K, Micluta MA, Petrescu AJ, Kinter M, Ganapathi R, Ganapathi MK.

Proteomics. 2011 Mar;11(5):829-42. doi: 10.1002/pmic.201000194. Epub 2011 Jan 31.

46.

CCL2 expression in primary ovarian carcinoma is correlated with chemotherapy response and survival outcomes.

Fader AN, Rasool N, Vaziri SA, Kozuki T, Faber PW, Elson P, Biscotti CV, Michener CM, Rose PG, Rojas-Espaillat L, Belinson JL, Ganapathi MK, Ganapathi R.

Anticancer Res. 2010 Dec;30(12):4791-8.

PMID:
21187454
47.

The nationwide study of bacterial pathogens associated with urinary tract infections conducted by the Japanese Society of Chemotherapy.

Ishikawa K, Matsumoto T, Yasuda M, Uehara S, Muratani T, Yagisawa M, Sato J, Niki Y, Totsuka K, Sunakawa K, Hanaki H, Hattori R, Terada M, Kozuki T, Maruo A, Morita K, Ogasawara K, Takahashi Y, Matsuda K, Hirose T, Miyao N, Hayashi T, Takeyama K, Kiyota H, Tomita M, Yusu H, Koide H, Kimura S, Yanaoka M, Sato H, Ito T, Deguchi T, Fujimoto Y, Komeda H, Asano Y, Takahashi Y, Ishihara S, Arakawa S, Nakano Y, Tanaka K, Fujisawa M, Matsui T, Fujii A, Yamamoto S, Nojima M, Higuchi Y, Ueda Y, Kanamaru S, Monden K, Tsushima T, Seno Y, Tsugawa M, Takenaka T, Hamasuna R, Fujimoto N, Sho T, Takahashi K, Inatomi H, Takahashi N, Ikei Y, Hayami H, Yamane T, Nakagawa M, Kariya S, Arima T.

J Infect Chemother. 2011 Feb;17(1):126-38. doi: 10.1007/s10156-010-0174-1. Epub 2010 Dec 21.

48.

DNA topoisomerase II enzymes as molecular targets for cancer chemotherapy.

Chikamori K, Grozav AG, Kozuki T, Grabowski D, Ganapathi R, Ganapathi MK.

Curr Cancer Drug Targets. 2010 Nov;10(7):758-71. Review.

PMID:
20578986
49.

Nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy in 2007: general view of the pathogens' antibacterial susceptibility.

Niki Y, Hanaki H, Matsumoto T, Yagisawa M, Kohno S, Aoki N, Watanabe A, Sato J, Hattori R, Terada M, Koashi N, Kozuki T, Maruo A, Morita K, Ogasawara K, Takahashi Y, Watanabe J, Takeuchi K, Fujimura S, Takeda H, Ikeda H, Sato N, Niitsuma K, Saito M, Koshiba S, Kaneko M, Miki M, Nakanowatari S, Honda Y, Chiba J, Takahashi H, Utagawa M, Kondo T, Kawana A, Konosaki H, Aoki Y, Ueda H, Sugiura H, Ichioka M, Goto H, Kurai D, Okazaki M, Yoshida K, Yoshida T, Tanabe Y, Kobayashi S, Okada M, Tsukada H, Imai Y, Honma Y, Nishikawa K, Yamamoto T, Kawai A, Kashiwabara T, Takesue Y, Wada Y, Nakajima K, Miyara T, Toda H, Mitsuno N, Sugimura H, Yoshioka S, Kurokawa M, Munekawa Y, Nakajima H, Kubo S, Ohta Y, Mikasa K, Maeda K, Kasahara K, Koizumi A, Sano R, Yagi S, Takaya M, Kurokawa Y, Kusano N, Mihara E, Kuwabara M, Fujiue Y, Ishimaru T, Matsubara N, Kawasaki Y, Tokuyasu H, Masui K, Negayama K, Ueda N, Ishimaru M, Nakanishi Y, Fujita M, Honda J, Kadota J, Hiramatsu K, Aoki Y, Nagasawa Z, Suga M, Muranaka H, Yanagihara K, Fujita J, Tateyama M, Sunakawa K, Totsuka K.

J Infect Chemother. 2009 Jun;15(3):156-67. doi: 10.1007/s10156-009-0674-z. Epub 2009 Jun 25.

50.

Kinase activity of the dgk gene product is involved in the virulence of Streptococcus mutans.

Shibata Y, van der Ploeg JR, Kozuki T, Shirai Y, Saito N, Kawada-Matsuo M, Takeshita T, Yamashita Y.

Microbiology. 2009 Feb;155(Pt 2):557-65. doi: 10.1099/mic.0.023812-0.

Supplemental Content

Loading ...
Support Center